May, Melanoma Awareness Month: Prevention, awareness and early diagnosis

May is internationally recognized as Melanoma Awareness Month and Skin Cancer Awareness Month, dedicated to raising awareness about prevention, sun protection, and the importance of early diagnosis.

Skin cancer is the most common type of cancer worldwide, with melanoma being its most aggressive form. Although it accounts for a smaller proportion of skin cancer cases, it is responsible for the majority of skin cancer-related deaths.

Globally, in 2020 there were approximately 325,000 new cases of melanoma and around 57,000 deaths, with numbers expected to rise in the coming years if prevention and awareness efforts are not strengthened.

In Europe, melanoma remains one of the most common cancers, with more than 100,000 new cases annually and over 15,000 deaths each year. The incidence is higher in Northern and Western European countries, while overall UV radiation exposure is considered the main contributing factor for the majority of cases.

Excessive exposure to ultraviolet (UV) radiation, whether from the sun or artificial sources such as tanning beds, is the most significant risk factor for melanoma. Many cases could be prevented through proper sun protection and behavioral changes.

In countries like Greece, where sunlight exposure is high throughout much of the year, awareness and prevention are especially important. Regular skin self-examinations and dermatological check-ups can play a key role in identifying suspicious changes in moles (naevi) at an early stage.

Early diagnosis significantly improves survival rates. When detected in its initial stages, melanoma is highly treatable, whereas delayed diagnosis is associated with more aggressive disease progression. This highlights the critical importance of awareness and timely medical evaluation.

Preventive measures remain essential: using sunscreen, avoiding peak sun hours, wearing protective clothing, and avoiding artificial tanning can all significantly reduce risk.

Melanoma Awareness Month serves as an important reminder that skin health is not only an aesthetic concern but a vital part of overall health and cancer prevention.

Read also Kapa3’s article on Bladder Cancer Awareness Month.

Sources:

  • World Health Organization (WHO)
  • International Agency for Research on Cancer (IARC) – GLOBOCAN
  • European Cancer Information System (ECIS)
  • European Environment Agency (EEA)

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Bladder Cancer Awareness Month: Awareness, prevention and early diagnosis

May is internationally recognized as Bladder Cancer Awareness Month, an important initiative led by health organizations and patient advocacy groups worldwide to promote public awareness, prevention, and early diagnosis.

Bladder cancer is among the most common types of cancer globally, with hundreds of thousands of new cases diagnosed each year. In Europe, it is considered one of the most common urological cancers, affecting men significantly more often than women.

In Greece, the data remains particularly concerning. The country records the highest incidence rate in Southern Europe, with approximately 39.7 new cases per 100,000 men annually. In terms of mortality, an estimated 7–8 men per 100,000 lose their lives to the disease every year, placing Greece among the countries with the highest mortality rates in the region. These figures highlight the importance of prevention, awareness, and timely medical intervention.

Behind every statistic are people — patients and families facing the emotional, physical, and practical challenges that accompany a cancer diagnosis. Raising awareness is therefore not only about numbers, but also about supporting individuals throughout their journey.

Smoking remains the most significant risk factor for bladder cancer and is linked to a large percentage of cases. Long-term exposure to certain chemicals, especially in specific occupational environments, as well as chronic inflammation of the urinary tract, may also increase the risk of developing the disease.

Recognizing the symptoms early can make a critical difference. The most common warning sign is blood in the urine (hematuria), even when no pain is present. Other symptoms may include frequent urination, burning during urination, or a sudden urge to urinate. Although these symptoms may also be associated with less serious conditions, they should never be ignored.

When bladder cancer is diagnosed at an early stage, survival rates are significantly higher, underlining the importance of early detection. However, the disease is also known for its high recurrence rates, making long-term follow-up and monitoring essential even after treatment.

Prevention remains a key pillar in reducing the burden of the disease. Quitting smoking, limiting exposure to harmful chemicals, and increasing awareness of the symptoms can all contribute to lowering the risk.

In Greece, awareness initiatives are also supported by scientific organizations such as the Hellenic Genito-Urinary Cancer Group (HGUCG), contributing to public education and the promotion of early symptom recognition.

Bladder Cancer Awareness Month is an important opportunity to encourage open discussion around the disease. Awareness is more than information — it is a tool that can lead to earlier diagnosis, improved treatment outcomes, and ultimately, more lives saved.

Sources:

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Mapping the efficiency of cancer care in Greece: findings from the All.Can Greece report

Cancer care efficiency in Greece remains one of the most complex and pressing challenges for the Greek health system — not only in terms of its clinical burden, but also in how care is organized around the patient.

With approximately 63,000 new cancer cases diagnosed annually and more than 32,000 cancer-related deaths each year, Greece faces a steadily increasing oncological burden. Projections suggest that cancer incidence will rise by around 23% by 2040, further intensifying pressure on health services.

Against this backdrop, All.Can Greece has published a landmark report titled “Mapping the Efficiency of Cancer Care in Greece”, based on the pilot implementation of the All.Can Action Guide for Efficient Cancer Care.

Rather than simply describing the current situation, the report aims to measure it — identifying where efficiency is lost across the cancer care pathway and where targeted reforms could make the greatest impact.

Cancer care efficiency in Greece: delays in care delivery

One of the most critical findings of the report relates to delays in the patient journey.

Despite the existence of modern infrastructure and highly specialized oncology centres, significant delays persist between initial suspicion, diagnosis, and the start of treatment.

These delays are not the result of a single bottleneck, but of systemic fragmentation:

  • fragmented referral pathways,
  • limited coordination between levels of care,
  • and the absence of standardized clinical protocols.

A key structural weakness is the lack of systematic monitoring of waiting times and time-to-treatment indicators. As a result, inefficiencies remain partially invisible to the system itself, limiting the ability to implement targeted improvements.

Fragmentation across the care continuum

The report highlights a broader issue of fragmentation in cancer care delivery.

The patient journey from primary care to specialist oncology services is often not clearly structured or consistently coordinated. Referral pathways depend heavily on individual practice rather than standardized national protocols.

A major gap is the absence of structured patient navigation services. In practice, this means that patients and families are often left to navigate a complex system on their own, increasing delays and adding unnecessary psychological burden.

At the same time, multidisciplinary tumor boards represent a positive development, supporting collaborative clinical decision-making across specialties. However, systematic monitoring of their performance remains limited.

The development of Comprehensive Cancer Centers is identified as a promising step forward, although further regulatory strengthening and clearer governance structures are still needed to maximize their impact.

Patient-centered care: progress with remaining gaps

Greece has made notable progress in collecting Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs), reflecting a growing commitment to integrating patient perspectives into care delivery.

However, patients’ access to their own clinical data remains limited, restricting their ability to actively participate in decision-making processes.

In addition, patient education and shared decision-making are not yet systematically embedded across the health system.

Another important gap concerns survivorship care. As cancer survival rates improve, the lack of structured long-term follow-up pathways leaves many patients without continuous support after active treatment ends.

Key policy directions

The report outlines several strategic priorities for improving cancer care efficiency in Greece:

  • Development of a comprehensive national cancer strategy with clear targets and governance mechanisms
  • Strengthening coordination across all levels of care
  • Implementation of standardized clinical pathways with defined time-to-treatment and quality indicators
  • Investment in oncology workforce capacity, particularly in shortage specialties
  • Establishment of structured patient navigation programmes
  • Acceleration of Comprehensive Cancer Center development
  • Systematic use of health data for monitoring performance and accountability
  • Greater patient engagement through PROMs, PREMs, and shared decision-making

Conclusion: a system with strong foundations but limited integration

Greece has many of the essential building blocks for a high-performing cancer care system — including infrastructure, clinical expertise, and emerging digital health capabilities.

However, the key challenge lies not in the existence of these components, but in their integration.

The All.Can Greece report highlights a system that is still operating in silos: strong individual elements that do not yet function as a fully connected care pathway.

In oncology, this lack of integration is not merely an organizational issue. It directly affects timeliness, patient experience, and ultimately outcomes.

The opportunity now lies in moving from fragmented capacity to coordinated care — where patients no longer have to bridge the gaps between system components themselves.

Source: Mapping-the-Efficiency-of-Cancer-Care-in-Greece-FINAL

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Additional Rebate on High-Cost Medicines for 2025: What the New Decision Foresees

 

 

 

MELODIC Online Symposium: completion of the pilot training phase and strengthening psychosocial cancer care

The European project MELODIC (Mental Health Support for Young Adults with Cancer), in which the Cancer Guidance Center – Kapa3 participates, is being implemented through distinct development phases. The pilot training programme for healthcare professionals is one of its core components, and within this framework, the MELODIC Online Symposium 2026, taking place on 24 April 2026, marks the completion of this educational phase.

The MELODIC project framework

MELODIC is a European project co-funded by the European Union, aiming to strengthen the mental health of young adults living with cancer, as well as to support their families. Through the collaboration of universities, research institutions and healthcare organizations across Europe, the project develops training and support tools for healthcare professionals.

More information about the project and its progress is available on the official Kapa3 website, in the dedicated project section.

The pilot training programme

The pilot training programme focused on enhancing the knowledge and skills of healthcare professionals in providing psychosocial support to young adults with cancer and their families.

As part of the programme, online sessions and contact lessons were delivered, aiming to strengthen interdisciplinary collaboration and support the practical application of tools in everyday clinical practice.

MELODIC Online Symposium 2026

The MELODIC Online Symposium 2026, a two-hour event, brings together participants from all partner countries and includes:

  • opening presentations from the European Cancer Organisation and Youth Cancer Europe
  • an “experts by experience” panel, where individuals share their lived experience
  • a networking panel with healthcare professionals from participating countries
  • discussion on how training can be applied in clinical practice
  • a closing session by the project coordination team

From training to clinical practice

A key objective of the MELODIC training programme is to strengthen the psychosocial dimension of cancer care, with particular focus on young adults.

The exchange of experiences among healthcare professionals contributes to more holistic approaches to care and supports the integration of psychosocial support into daily clinical practice.

The role of Kapa3

Kapa3 actively participates in the European MELODIC consortium, contributing to the implementation of the training activities and the dissemination of results in Greece. Through this involvement, the connection between scientific knowledge and the support of cancer patients is further strengthened, promoting the development of practical approaches to psychosocial care.

The MELODIC Online Symposium 2026 marks the transition from the pilot training phase to the next stage of utilizing its outcomes, reinforcing the link between education and real-world application in cancer care.

The Press Release here: PRESS-RELEASE-MELODIC SYMPOSIUM

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 and Karkinaki join forces to support children, adolescents, and families living with cancer

The Cancer Guidance Center – Kapa3 announces its new collaboration with the non-profit organization “Karkinaki”, aiming to strengthen information, psychosocial support, and awareness around childhood and adolescent cancer, as well as to support families experiencing the disease.

Karkinaki is a specialized organization working in the field of childhood and adolescent cancer, focusing on reliable information, empowering parents and caregivers, and fostering a supportive environment around children and teenagers affected by cancer. Through community-based actions and awareness initiatives, it seeks to reduce the sense of isolation that often accompanies diagnosis, while also enhancing understanding, social awareness, and access to available support resources for families.

Within the framework of this collaboration, the two organizations will develop joint initiatives focused on information and awareness-raising, with an emphasis on actions addressing both families and healthcare and support professionals. The partnership will also include the co-organization of informational events, the exchange of good practices, and the exploration of participation in national and European programs that promote a holistic approach to patient care, with an emphasis on continuity of support across all stages of the disease experience.

The Cancer Guidance Center – Kapa3 is dedicated to informing, guiding, and empowering people affected by cancer, providing practical support and access to reliable information and services. At the same time, it develops initiatives that strengthen patients’ active participation in managing their health and promotes a more accessible and human-centered model of care.

In this context, Kapa3 is also involved in European collaborations focusing on the psychosocial dimension of cancer across different stages of life, such as the MELODIC project, which addresses the mental health of young adults with lived experience of cancer. This work further enhances the organization’s ability to recognize needs that emerge throughout the cancer journey, from childhood to adulthood.

This collaboration with Karkinaki reflects the shared vision of both organizations to strengthen a support network that goes beyond medical treatment, extending into families’ daily lives, information access, and psychosocial empowerment, with the aim of providing a more stable and meaningful presence for those who need it most.

Our Press Release here: KARKINAKI PRESS RELEASE

Text: Ifiyenia Anastasiou for Kapa3

Digital Access to Test Results: An Important Right for Patients

Digital access to medical test results has become an important right for patients in Greece, following new regulations that strengthen the use of the Digital Repository of Diagnostic Laboratory Results. According to the relevant decision published in the Government Gazette (March 2026), public and private healthcare units collaborating with EOPYY are required to record diagnostic test results in digital form within a specified timeframe.

This change is not just a technical procedure or an administrative obligation for healthcare providers. In practice, it represents a meaningful enhancement of patients’ rights, ensuring that every citizen can have immediate and organized access to their medical data.

Digital access to test results now reduces the need for physical documents, printed copies, or trips to diagnostic centers. Instead, results are stored in a unified digital environment connected to the Individual Electronic Health Record. This allows patients to have their test history consolidated, reducing the risk of losing important information.

For people living with cancer, this development is especially significant. Disease monitoring often involves repeated tests, visits to different doctors, and continuous evaluation of results. Immediate access to all data facilitates collaboration among healthcare professionals and contributes to more coordinated and effective care.

Moreover, the obligation to record results is linked to reimbursement procedures through EOPYY, enhancing transparency in the healthcare system. This ensures that only tests that have actually been performed are reimbursed, limiting abuse and strengthening the reliability of services.

It is also worth noting that data management is carried out under the current personal data protection framework, safeguarding patients’ privacy and information security.

Transitioning to a more digital healthcare system is not just a technological advancement. It is a step toward a more human, transparent, and accessible system of care, where the patient has an active role and meaningful control over their own data.

Ultimately, strengthening digital access to test results represents an important step forward in empowering patients and improving the quality of healthcare provided.

Source: Government Gazette, FEK B’ 1503/17.03.2026

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Kapa3 at the Scientific Meeting “Cancer in 2026: Challenges and Disruptions” – Focusing on Supportive Care and Its Limits

At the scientific meeting “Cancer in 2026: Challenges and Disruptions”, held on March 13–14, 2026 at the Divani Caravel, Kapa3 actively contributed to discussions on supportive care for oncology patients, a critical area for improving quality of life and holistic patient support.

The meeting was organized by the Hellenic Oncology Patient Support Institute, under the chairmanship of Christos Panopoulos, and was held under the auspices of the Hellenic Cancer Society and the Hellenic Society of Medical Oncologists. It has become a recognized annual event for the oncology community, highlighting each year the latest challenges and rapid developments in the field.

Progress in oncology is continuous and impressive, with scientific advances steadily enhancing the possibilities for personalized treatment, while simultaneously improving patients’ quality of life and turning some forms of cancer into manageable chronic conditions.

During the two-day meeting, key developments were presented in critical areas such as precision medicine, immunotherapy, and novel therapeutic strategies, with particular emphasis on the role of artificial intelligence and molecular analysis in modern clinical practice.

Kapa3 participated in the roundtable on supportive care for oncology patients, held on Friday, March 13, represented by Ms. Evangeli Bista. She noted that attending the conference gave her the opportunity to engage with people leading initiatives in patient support and advocacy. The roundtable addressed critical topics such as the role of healthcare professionals, pain management in Greece, and the adequacy of existing care structures.

In the discussion on psychosocial support, Ms. Bista, representing Kapa3 and drawing from her daily experience with oncology patients, emphasized that addressing the challenges arising from the patient journey is particularly demanding, as the high volume of cases and the fragmentation of the healthcare and social support system create exponentially more issues to manage.

When asked whether voluntary work alone is sufficient to meet the growing needs of patients, her response was clear:

…voluntary action is a valuable and essential pillar of social support. The improvement of patients’ quality of life relies heavily on voluntary efforts that take place across the country under challenging conditions. However, it is not sufficient on its own to meet the complex and increasing needs of patients.

As highlighted during the discussion, voluntary contributions are crucial for filling gaps in the system and strengthening social protection. At the same time, a more comprehensive and institutionally supported approach is necessary. This includes:

• adequate and stable funding
• continuous training and empowerment of all stakeholders
• clear and functional legal frameworks
• a shift in mindset among healthcare professionals, patients, and administrators
• and the development of integrated policies in the field of supportive care

Kapa3’s intervention underscored the importance of psychosocial support as an integral part of oncology supportive care, promoting a more holistic, humane, and sustainable approach to patient management. As Ms. Bista noted, participating in the two-day meeting serves as a reminder that the fight to support patients requires all of us on the same side.

March – Multiple Myeloma Awareness Month

March – Multiple Myeloma Awareness Month

March is internationally recognized as Multiple Myeloma Awareness Month, a type of blood cancer that affects plasma cells – immune system cells responsible for producing antibodies and defending the body against infections.

This period provides an important opportunity to raise public awareness, highlight the challenges faced by patients, and enhance understanding of the disease, early diagnosis, and the importance of access to modern treatments.

What is Multiple Myeloma

Multiple myeloma develops in the bone marrow, when plasma cells grow uncontrollably and produce abnormal proteins. The presence of these cells can affect the production of healthy blood cells, cause bone damage, and impair the function of vital organs such as the kidneys. Although relatively rare, it is the second most common blood cancer worldwide.

The disease’s symptoms may be initially nonspecific and develop gradually. Fatigue, bone pain – especially in the spine or ribs – frequent infections, anemia, or kidney problems are some of the signs that may prompt further investigation. Early awareness and timely medical evaluation are therefore crucial for diagnosis and disease management.

Multiple Myeloma by the Numbers

Globally, the disease affects a significant number of people. According to international epidemiological data:

  • 188,000 new cases were reported worldwide in 2022

  • Approximately 121,000 people died from the disease the same year

  • It is estimated that more than 540,000 people are currently living with multiple myeloma worldwide

The disease occurs more often in older adults. Most diagnoses occur in people over 60–65 years old, and around 80% of cases are reported in individuals over 65. Experts predict that the disease’s incidence may rise in the coming decades, largely due to the aging population in many countries.

The Situation in Greece

In Greece, the exact epidemiological picture of multiple myeloma is not fully clear, as there is no comprehensive national cancer registry recording all cases systematically.

However, according to available international estimates for 2022:

  • About 763 new multiple myeloma cases were reported in the country

  • Approximately 579 deaths were attributed to the disease

  • It is estimated that around 2,154 people in Greece are living with the disease over a five-year period

These figures highlight the importance of improving health data collection and continuously supporting patients living with the disease.

Advances in Treatments

In recent years, scientific progress has significantly changed the course of the disease.

Modern therapies include:

  • Immunotherapies

  • Monoclonal antibodies

  • Proteasome inhibitors

  • Immunomodulatory drugs

  • CAR‑T cell therapies (for advanced stages of the disease)

New therapeutic combinations and ongoing clinical studies are providing more treatment options, reinforcing hope for even more effective therapies in the future.

The Importance of Awareness and Support

Despite these advancements, public awareness and support for people living with the disease remain crucial. Early diagnosis, access to specialized medical care, and equitable access to modern therapies are key factors in improving disease outcomes and patients’ quality of life.

Multiple Myeloma Awareness Month serves as a reminder that knowledge, research, and collective effort can make a difference. Through education, support for scientific research, and assistance to patients and their families, we can help create an environment where no one faces cancer alone.

Sources:

https://gco.iarc.fr
(Global Cancer Observatory – International Agency for Research on Cancer)

https://pubmed.ncbi.nlm.nih.gov/39658225/
(Global burden and projections of multiple myeloma)

https://www.oecd.org/health/cancer-profiles/greece.html
(EU Country Cancer Profile – Greece)

https://ehoonline.biomedcentral.com/articles/10.1186/s40164-025-00684-x
(Global epidemiology of multiple myeloma)

https://pmc.ncbi.nlm.nih.gov/articles/PMC3627436/
(Multiple myeloma epidemiology study)

Text/adaptation: Ifiyenia Anastasiou for Kapa3